GetCoattail Research — a filings audit of PTC Therapeutics, Inc. (PTCT) through six filing lenses, as of the latest filings. Past patterns are not a promise of future results. For education only — not investment advice.
The Hype
PTC Therapeutics, Inc. (PTCT) is the issuer behind this audit — CIK 1070081, common-stock CUSIP 69366J200, class COM, listed on Nasdaq, industry Pharmaceutical Preparations (SIC 2834). Revenue, all from the fundamentals series, was $937,822,000 in 2023, $806,780,000 in 2024 and $1,730,655,000 in 2025 (+114.5%), on total assets of $2,898,767,000 — against equity of −$205,313,000, a negative book value. Net income was $682,644,000 in 2025, after a 2024 loss of −$363,295,000. Shares outstanding are 83,544,284 (October 27, 2026) — about $5.0 billion at the latest close.
The price file fell hard from its summer high. PTCT closed at $60.23 on November 18, 2026 (open $59.99, high $60.80, low $59.86, volume 640,646) — down 4.28% over 21 trading days (from $62.92 on October 20), down 14.59% over 63 (from $70.52 on August 20), down 26.16% since June 30 ($81.57), and down 21.46% from a year ago ($76.69). The cache holds 502 trading days, from November 18, 2024 (first close $39.23) to November 18, 2026 — the highest close is $89.55 (July 9, 2026), the lowest $36.19 (May 6, 2025), all-available-cache-history figures with no full-year label.
Why this audit now: on November 3, the board authorized a $500 million share repurchase program — the company buying its own stock while the price fell — and on October 29 it reported third-quarter results (8-K Item 2.02). The filings since tell a different story: the largest tracked holder cut 79% in Q3, insiders sold $7.7 million with zero buys in 90 days, and the short ledger shrank by half. The question is what the filings recorded while the price fell 26.16% from the June 30 close: did the tracked funds, the broad base, insiders, the control register, or the short ledger move with the fade? Congress contributes no countable finding — its panel is unavailable.
The Tape
| Lens | As of | What the filings show | Direction vs prior period |
|---|---|---|---|
| Superinvestors (13F) | Jun 30, 2026 | 3 of 147 tracked managers hold; 7,820,431 shares ($637,912,557). RTW is 99.05%, UNCHANGED. | NEW 1, UNCHANGED 2; exits: none — Q3 cut in the table below |
| All institutions (13F) | Jun 30, 2026 | 382 holders (381 long) hold 100,298,101 shares ($8,026,124,408). | Shares +16.22%; holders +39 net (368 entered, 329 exited) |
| Insiders (Form 4) | Oct 16, 2026 (form4full w90); Nov 18, 2026 (site 90d) | Form4full w90: 0 buys vs 27 sells ($8,457,867.04). Site 90d: 0 buys vs 27 sells ($7,722,030.65) — Steele sell now included. | Both windows zero buys; three-way reconciliation is exact |
| Congress | Nov 16, 2026 | Panel unavailable; staging holds 0 rows. | Availability statement, not a count; no total claimed |
| 13D/G | Nov 16, 2026 (agg) | Aggregate (common-CUSIP basis): 19 filings, 17 reporters, max 14.8%. RTW's 13G/A confirms its Q3 cut. | As-filed row sum 149,708,458 shares (not shares held); scan counts 21 accessions |
| Short interest | Oct 15, 2026 | 8,303,282 shares short, 7.59 days to cover, 9.94% of shares outstanding; fails 0. | Short down 52.05% from Jun 30; fails down from 124,368 |
Superinvestors. Three of 147 tracked managers hold 7,820,431 shares — $637,912,557 reported. RTW Investments holds 7,746,415 shares (99.05% of the tracked stake and value, 5.39% of its portfolio), UNCHANGED, filed August 14, 2026. The other two are small beside it: OrbiMed Advisors holds 49,100 shares (0.6%, 0.07% of its portfolio), UNCHANGED, filed August 14, 2026; Polen Capital Management holds 24,916 shares (0.3%, 0.02% of its portfolio), NEW, filed August 4, 2026. NEW is scoped tightly: the register's Q1-to-Q2 label for Polen's tracked row — its first tracked-13F appearance for PTCT in Q2, not a claim about Polen's earlier holdings. No PTCT option rows sit in the register; no tracked name exited in Q2. The tracked stake is 7.80% of all institutions' shares and 7.95% of their value. Denominator: 147 funds with usable Q2 data, not the 149-fund roster.
| Fund | Shares Q2 | Value Q2 | Shares Q3 | Value Q3 | Shares change | Filed |
|---|---|---|---|---|---|---|
| RTW Investments | 7,746,415 | $631,875,072 | 1,615,819 | $104,672,755 | −79.14% | Nov 16, 2026 |
| OrbiMed Advisors | 49,100 | $4,005,087 | 49,100 | $3,180,698 | 0.0% | Nov 16, 2026 |
| Polen Capital Management | 24,916 | $2,032,398 | 11,569 | $749,440 | −53.57% | Nov 13, 2026 |
| Tracked total | 7,820,431 | $637,912,557 | 1,676,488 | $108,602,893 | −78.56% |
Q3 update — filed November 2026, after the Q2 audit window. RTW Investments cut its PTCT stake 79.14% in Q3, to 1,615,819 shares ($104,672,755) from 7,746,415 shares ($631,875,072) in Q2, filed November 16, 2026 (accession 0001493215-26-000214). Polen Capital Management cut 53.57%, to 11,569 shares ($749,440) from 24,916 shares, filed November 13, 2026 (accession 0001172661-26-005017). OrbiMed Advisors held 49,100 shares, unchanged, filed November 16, 2026 (accession 0001172661-26-005349). The three total 1,676,488 shares ($108,602,893) in Q3, with RTW still 96.38% of the tracked stake. This note does not rebase the article: the headline and the Tape table stay Q2-based.
All institutions. The broad base grew into the decline. Holders rose by 39 net to 382, of which 381 are long, while shares rose 16.22% (from 86,299,172 to 100,298,101) and value rose 38.7% (from $5,787,696,462 to $8,026,124,408). Behind the net +39, 368 filers entered and 329 exited.
Insiders. Three exact figures, each for its own collection. In the form4full 90-day window (filing dates July 19 to October 16, 2026): 0 buys, 27 sells — 122,370 shares for $8,457,867.04, from 4 sellers, across 12 filings; the 27-row detail file re-sums exactly to the cent. The window is filing-date based; all 27 P/S transaction dates (August 4 to October 14, 2026) fall inside it. By seller: Schmertzler Michael, director, 20 / 95,000 / $6,620,968.68; Steele Glenn Jr, director, 1 / 12,000 / $781,920.00; Klein Matthew B., officer, CEO, 1 / 10,292 / $705,722.44; Boulding Mark Elliott, officer, Exec. VP and CLO, 5 / 5,078 / $349,255.92. In the site 90-day window (to November 18, 2026): 0 buys, 27 sells for $7,722,030.65, from 3 sellers — a figure the stock-page insider panel agrees with ("27 sales by 3 insiders ($7.7M)"). The October build's trap is gone: Steele's September 30 sell — 12,000 shares at $65.16 ($781,920.00), filed October 2, accession 0001269131-26-000005 — is now in the site aggregate. One Form 4 was filed after the October 16 cutoff: Boulding Mark Elliott, filed November 18, 2026 (accession 0001578852-26-000028), three sells transacted November 16 totalling 2,812 shares for $174,013.31; its paired M row (2,812 shares at $25.69, an option exercise) is excluded from P/S — the exercise and the sales are the same share count, a sell-to-cover shape. The reconciliation is exact: form4full $8,457,867.04 minus early-window sells (filed July 19 to August 19: 3 sells / $909,849.70) plus the November 18 filing $174,013.31 equals site $7,722,030.65. Sells 27 − 3 + 3 = 27; sellers 4 − 1 (Klein) = 3. The wider windows agree: the 1-year aggregate (filing dates November 19, 2025 to November 18, 2026) holds 0 buys against 206 sells (737,513 shares, $56,398,870.91, 13 sellers, 86 filings); the all-time aggregate holds 0 buys against 312 sells (1,179,331 shares, $82,168,873.56, 14 sellers, 139 filings).
Congress. This lens reports an availability statement, not a count. The site panel as of November 16, 2026 reads: "Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026)." The staging file holds zero PTCT rows. Neither is a verified count: no zero-trades claim is made. Any claim beyond that would need a direct PTR search first.
13D/G. The control register needs its collection label first. The aggregate, on a common-CUSIP (69366J200) basis, counts 19 filings (0 Schedule 13D, 19 Schedule 13G, 12 amendments), 17 reporters, maximum reported stake 14.8%, latest filing November 16, 2026. Its as-filed reporter-row sum is 149,708,458 shares — a sum of rows, never shares held. A parsed-corpus scan under the same issuer CIK 1070081 counts 21 accessions, 35 reporter rows, an as-filed sum of 165,733,930 shares, 17 distinct reporter names — same latest date and maximum. All 21 scan filings are Schedule 13G or 13G/A — there is no 13D in the scan. The entire gap is two filings, both named: two Armistice Capital, LLC / Steven Boyd joint Schedule 13G/A filings on CUSIP 50127T109 — each reported twice, so 4 rows totaling 16,025,472 as-filed shares, exactly the gap (165,733,930 − 149,708,458 = 16,025,472). The security type of CUSIP 50127T109 is not determined here. Three filings arrived after the May 15, 2026 latest, all with event date September 30, 2026: Wellington Management Group LLP filed a Schedule 13G on November 16 for 5,287,260 shares, 6.3% (up from 4.8% in February); State Street Corporation filed a Schedule 13G on November 10 for 5,512,555 shares, 6.6% (up from 5.2%); and RTW Investments, LP filed Schedule 13G/A Amendment 6 on November 16 for 1,615,819 shares, 1.9% — the same count as its Q3 13F, an independent confirmation of the cut, and below the 5% line. Joint-filing warning: group members report the same shares repeatedly, so as-filed sums are never presented as shares owned.
Short interest. The bear trade shrank by more than half. FINRA short interest: 8,303,282 shares at October 15, 2026, 7.59 days to cover, 9.94% of shares outstanding (8,303,282 / 83,544,284). The series fell from 17,315,032 (June 30) to 8,303,282 (October 15) — down 52.05%, with October 15 the lowest print of the eight. Fails need a settlement label: 124,368 fails on June 30, 2026 — 0.7183% of that day's short interest (124,368 / 17,315,032), then 0 on all seven later settlements including October 15. Fails figures come from the site's fails file only (SEC semi-monthly files); the stock page has no fails panel for PTCT. The October 31 settlement (file shrt20261030.csv) is not yet in the FINRA collection as of the November 16 collector run.
The Gap
The sharpest tension is timing, not direction. The Q2 snapshot shows a holder that did not move and a broad base that added — RTW unchanged, all institutions up 16.22% — but the snapshot ends June 30, when the close was $81.57. The fall to $60.23 happened after it. The Q3 filings answer it: RTW cut 79.14% through the fade, and its own Schedule 13G/A confirms the same 1,615,819 shares. Reading the Q2 hold as a call on the November price mistakes a lagging picture for a live one.
Concentration cuts both ways, and the buyback sharpens it. RTW alone is 99.05% of the tracked Q2 stake, so "three funds hold" is mostly one fund's decision — and the Q3 cut, not the Q2 hold, is the tracked lens's story now. The company, meanwhile, authorized a $500 million repurchase on November 3 while its largest tracked holder was selling and insiders sold $7.7 million with zero buys — conviction and flow point in opposite directions. The control register did not simply shrink — it turned over: RTW fell below 5% while Wellington rose to 6.3% and State Street reported 6.6%. For scale: the 90-day insider window ($7.7 million sold) looks small beside the 1-year window ($56.4 million), and the short trade shrank by more than half while the price fell 26.16%.
What Would Change the Picture
What would change this audit's findings:
- Q4 13F season (due by February 2027). Watch whether RTW kept cutting, stabilised, or rebuilt after its 79.14% Q3 cut — and whether any tracked name exited.
- Buyback execution. The November 3 authorization is not purchases: whether the company actually repurchases shares, and at what pace, would test the board's conviction against the filings' flow.
- An insider buy in any window would break a tape showing zero buys in both 90-day windows and the 1-year window.
- Continued insider selling into Q4 — a further Form 4 after Boulding's November 18 filing — would extend a tape that already runs 312 sells with zero buys all-time.
- A parsed congress transaction, or a direct PTR search, would replace an unavailability statement with a finding.
- A filing that names the security behind CUSIP 50127T109 would resolve the scan-versus-aggregate collection split.
- A Schedule 13D filing would change a register whose scan holds zero 13D filings.
- Short-interest direction. A rise back toward the June 30 count of 17,315,032 shares, or a fails repeat of 124,368, would give the short lens something new.
As-of & Limits
| Lens | As of | Limit or note |
|---|---|---|
| Superinvestors (13F) | Jun 30, 2026 | 13F figures are as of June 30, 2026, the quarter-end. Funds have up to 45 days after quarter-end to file, so this is the most recent complete picture — and it is always a lagging one. Single CUSIP 69366J200 for the 13F register. Denominator 147 = funds with usable Q2 data (roster 149); the stock page hero says "held by 3 of 149." Polen NEW is the register's Q1-to-Q2 change label for Polen Capital Management's tracked row for this ticker only. Q1 share counts per holder are not in any workspace file found, so direction labels and rounded change percentages only are stated; no Q1 share count is backed out from a rounded percentage. Q3 figures appear in the Q3 update note and table in The Tape; the headline and the Tape table stay Q2-based. |
| All institutions (13F) | Jun 30, 2026 | By-ticker row is the SEC 13F dataset row for PTCT. 382 holders, 381 long — the gap is stated, never smoothed into a single long count. |
| Insiders (Form 4) | Oct 16, 2026 (form4full w90); Nov 18, 2026 (site 90d) | This lens counts only P and S codes. Form4full w90 (filing dates July 19 to October 16, 2026): 12 filings counted, 27 P/S rows from 11 accessions — the 12th is Sollie-Zetlmayer Hege Elisabeth (accession 0002142653-26-000004, filed July 30, 0 P/S rows) — 0 buys, 27 sells (122,370 shares, $8,457,867.04). The window rule is filing-date based; for PTCT all 27 P/S transaction dates (August 4 to October 14, 2026) also fall in July 19 to October 16, 2026. Site 90d to November 18, 2026: 0 buys, 27 sells ($7,722,030.65, 3 sellers) — Steele's September 30 sell ($781,920.00) is now included in the site aggregate, and the three-way reconciliation is exact (form4full $8,457,867.04 minus early-window sells $909,849.70 plus the November 18 Boulding filing $174,013.31 equals site $7,722,030.65). The parsed transaction-date set on or after August 20 holds 22 sells ($6,631,463.69, 3 sellers); it does not match the site figure because the site selects by filing date. One Form 4 was filed after the October 16 cutoff: Boulding Mark Elliott, filed November 18, 2026 (accession 0001578852-26-000028), three sells transacted November 16 for $174,013.31, plus a paired M row (2,812 shares at $25.69) excluded from P/S. The 1-year (filing dates November 19, 2025 to November 18, 2026: 86 filings, 206 sells, $56,398,870.91, 13 sellers) and all-time (139 filings, 312 sells, $82,168,873.56, 14 sellers) windows are cited from the aggregate only; detail was verified for the 90-day window, not for those windows. A writer publishing later must re-check all windows. |
| Congress | Nov 16, 2026 | Panel unavailable as of November 16, 2026; staging holds 0 PTCT rows. Neither is a verified count: no congress total is stated, and no zero is claimed. Any congress claim beyond the panel's unavailability would need a direct PTR search first. |
| 13D/G | Nov 16, 2026 (agg) | Collection-scoped phrasing: the headline count (19 filings, 17 reporters, 149,708,458 as-filed row shares) is the aggregate count on a common-CUSIP (69366J200) basis, latest filing November 16, 2026. The issuer-wide parsed-corpus scan counts 21 accessions, 35 rows, 165,733,930 shares, 17 names. The gap is two Armistice Capital / Steven Boyd joint Schedule 13G/A filings on CUSIP 50127T109 (4 rows, 16,025,472 shares). The 50127T109 security type is not determined. As-filed sums double-count joint reporters and are never presented as shares owned. The scan holds no 13D filings. The three filings after May 15, 2026 (Wellington 6.3%, State Street 6.6%, RTW 13G/A 1.9%) are parsed from their EDGAR XML; the pipeline aggregate is stale at May 15, 2026, so the aggregate entry here is recomputed from the scan plus those filings. The 2021–2024 corpus (37 rows, all PTC Therapeutics, Inc.) is a separate collection and is never merged into this series. |
| Short interest | Oct 15, 2026 | Shares-outstanding count is the stock page's base (9.94% at October 15). Fails are SEC semi-monthly prints from the site fails file only; the stock page has no fails panel for PTCT. Fails ratios are fails as a percent of short interest, never fractions. The series is reported as settlements, not as a signal. The October 31 settlement (file shrt20261030.csv) was not in the FINRA collection as of the November 16, 2026 collector run. |
| 8-K filings | Nov 3, 2026 | Latest three on the stock page block, latest first: November 3, 2026 (Items 7.01/8.01/9.01) — the $500 million share repurchase program, Exhibit 99.1 (accession 0001104659-26-121713); October 29, 2026 (Items 2.02/7.01/9.01) — third-quarter 2026 results; September 21, 2026 (Items 7.01/8.01/9.01). Item labels plus the filed exhibit for November 3; no further characterisation of the filings is made here. |
| Prices | Nov 18, 2026 | Price file: daily-refresh cache (fetchedFor November 18, 2026). Closes are the site's daily-refresh cache bars, not dividend-adjusted total return. The article's price as-of date is November 18, 2026; the November 19 close did not exist at writing time (U.S. market open), so a writer publishing later must refresh the price file and recompute the price context. History covers 502 trading days from November 18, 2024 only, labeled as all available cache history, with no full-year label. |
| Fundamentals | FY2025 | Issuer CIK 1070081. FY revenue, net income, total assets, and equity from the package's fin_series entry for 2023–2025 only. Shares outstanding from the stock page (as reported October 27, 2026). Market capitalisation of about $5.0 billion is computed at the November 18, 2026 close of $60.23. Exchange is Nasdaq with no tier stated. No stock-page red-flag claim is imported here. |
Methodology & disclaimer: 13F holdings are long shares unless stated; reported values include option rows for the all-institutions lens by definition. Short interest is FINRA twice-monthly settlements. Trading costs and taxes are not reflected in any figure. Past patterns are not a promise of future results. For education only — not investment advice.
This article describes filings and market data for education. It is not investment advice. Data: SEC EDGAR 13F (as of June 30, 2026, filed within 45 days), Q3 13F update note (RTW and Polen, filed November 2026), Form 4 aggregates checked through October 16, 2026 (form4full 90-day window) and November 18, 2026 (site 90-day window, with the Steele sell now included in the site aggregate and the November 18 Boulding filing counted), Congress panel as of November 16, 2026 (unavailable), SC 13D/G aggregate through November 16, 2026 on a common-CUSIP basis plus a parsed-corpus scan, FINRA short interest at October 15, 2026 settlement. 13F covers long positions of $100M+ managers only and is always a lagging picture. Trading costs and taxes are not reflected.
Related research: Seventeen of 147: Eagle Is 39.8% of the Tracked MercadoLibre Stake — and the Cohort Grew 11.8% While the Price Slipped 1.8% in Q2 · Seven of 147: GQG Is 93.7% of the Tracked Petrobras Stake — and It Added While the Price Fell 22.1% in Q2 · Six of 147: Baker Bros. Holds Nearly Half the Tracked Insmed Stake — and Insiders Sold $42.9M With Zero Buys in 90 Days · Track the tape on PTCT's stock page and the 13F filing season hub.
Revision history: v1.0 — November 19, 2026. Initial publication. Signals and lens aggregates: ptct_13f_holders_q2.csv · ptct_13f_holders_q3.csv. Insider trades: ptct_insider_form4_w90.csv · ptct_insider_form4_20261118.csv. Insider aggregates: ptct_insider_aggregates.csv. Short-interest series: ptct_short_interest_ftd.csv. 13D/G rows: ptct_scdg_13dg.csv. 13D/G aggregate entry: ptct_scdg_agg_entry.csv. Exits: ptct_13f_exited_q2.csv.